A Milestone for CRISPR Medicine
The U.S. Food and Drug Administration has expanded the approval of Casgevy (exagamglogene autotemcel), the world's first CRISPR-based gene therapy, to include children aged 5 to 11 suffering from sickle cell disease (SCD). The decision marks a major step forward in pediatric genomic medicine, extending a potentially curative therapy to a younger and more vulnerable patient population.
Sickle cell disease is a genetic blood disorder caused by a single point mutation in the gene encoding beta-globin, a component of hemoglobin. This mutation causes red blood cells to become rigid and sickle-shaped, leading to chronic hemolytic anemia, recurrent painful vaso-occlusive crises (VOCs), progressive organ damage, and significantly shortened life expectancy. For children with SCD, the burden is especially severe — frequent hospitalizations, missed school days, and the constant threat of stroke, acute chest syndrome, and other life-threatening complications.
Until recently, the only potential cure for SCD was a hematopoietic stem cell transplant from a matched sibling donor, a procedure available to fewer than 20 percent of patients due to the lack of suitable donors. For the remaining majority, treatment consisted of symptom management with hydroxyurea, chronic blood transfusions, and supportive care.
Casgevy changes that equation fundamentally.
How Casgevy Works
Casgevy is a CRISPR-Cas9 gene-editing therapy developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics. The treatment uses the patient's own hematopoietic stem cells, harvested via apheresis, which are then edited ex vivo using CRISPR-Cas9 technology.
The editing targets the BCL11A gene, a naturally occurring repressor of fetal hemoglobin production. By disrupting BCL11A in erythroid precursor cells, Casgevy reactivates the production of fetal hemoglobin (HbF) — the form of hemoglobin that all humans carry before birth. Fetal hemoglobin has a higher affinity for oxygen than adult hemoglobin and, crucially, does not polymerize under deoxygenated conditions the way sickle hemoglobin does. By boosting HbF to sufficiently high levels — typically above 30 percent of total hemoglobin — Casgevy effectively prevents red blood cells from sickling.
The edited stem cells are then infused back into the patient following a conditioning regimen of busulfan chemotherapy, which clears the bone marrow to make room for the corrected cells. The entire process, from stem cell harvest to infusion, takes several months and requires prolonged hospitalization.
The result, for the majority of treated patients, is a durable, transfusion-free state with no further vaso-occlusive crises. In the pivotal CLIMB-111 and CLIMB-121 clinical trials, 97 percent of evaluable patients achieved freedom from severe VOCs for at least 12 months post-treatment. Fetal hemoglobin levels rose from a baseline of roughly 5 percent to between 30 and 50 percent — well above the threshold needed to prevent sickling.
Why the Pediatric Expansion Matters
Casgevy was initially approved by the FDA in December 2023 for patients aged 12 and older with sickle cell disease, and for transfusion-dependent beta-thalassemia. The new approval extends the therapy to children as young as 5, expanding the eligible patient population significantly.
The pediatric population is where the intervention may have the greatest impact. Sickle cell disease often manifests earlier and more severely in children. Stroke risk peaks in early childhood. Irreversible organ damage — to the spleen, kidneys, lungs, and brain — accumulates from a young age, shortening life expectancy even if the acute crises are managed. By intervening early, Casgevy may prevent the cascade of organ damage that defines the natural history of the disease.
Children also tend to tolerate the conditioning regimen and transplant process differently than adults. Younger patients generally have better bone marrow reserve, fewer comorbidities, and a more robust capacity for hematopoietic recovery. The expanded approval means that pediatric hematologists can now discuss Casgevy as a treatment option with families of severely affected children before the disease has run its destructive course.
Clinical Data Supporting the Expansion
The FDA's decision was based on data from the ongoing CLIMB-121 phase 3 trial, which enrolled patients aged 5 to 11. Among the pediatric cohort, the results mirrored those seen in older patients. All treated children achieved sustained hemoglobin production above 9 g/dL within three months, with fetal hemoglobin levels rising to a mean of 35 percent. No severe vaso-occlusive crises were reported among treated patients during the follow-up period, which now extends to more than two years for the earliest pediatric enrollees.
Safety data showed a profile consistent with the known risks of the procedure. Adverse events were primarily related to the busulfan conditioning regimen — mucositis, febrile neutropenia, and infections — rather than the gene editing itself. No cases of insertional mutagenesis or off-target editing leading to clinical consequences were reported, though long-term follow-up is ongoing.
Vertex has committed to following all treated patients for 15 years through a long-term follow-up registry and observational study, monitoring for late-emerging effects including malignancy, germline editing, and hematopoietic stem cell clonal expansion.
Access and Pricing Challenges
Casgevy is priced at $2.2 million per patient in the United States, positioning it among the most expensive single-dose therapies ever approved. Vertex has negotiated outcomes-based agreements with several major insurers, under which payment is contingent on the patient remaining transfusion-free for a defined period.
For pediatric patients, the cost considerations are different. A 5-year-old child with severe SCD faces decades of potential medical expenses: emergency room visits, hospitalizations, chronic transfusions (each approximately $2,000 to $5,000 per visit), iron chelation therapy, lifelong hydroxyurea, and the management of end-organ complications including stroke, renal failure, and avascular necrosis of the hip. Over a lifetime, the cost of conventional management of severe SCD can exceed $10 million. From this perspective, Casgevy appears cost-effective despite its high upfront price.
Medicaid covers approximately 50 percent of children with SCD in the United States, and the Centers for Medicare and Medicaid Services has indicated that Casgevy will be covered for eligible children. Vertex offers patient assistance programs for uninsured and underinsured families.
Implications for the Field
The pediatric expansion of Casgevy carries implications well beyond sickle cell disease. It demonstrates that CRISPR-based gene therapies can be safely and effectively deployed in young children, opening the door to pediatric applications of gene editing for other genetic disorders.
Several CRISPR-based therapies are now in the pipeline. Vertex is developing CTX001 for transfusion-dependent beta-thalassemia in younger children. Editas Medicine is pursuing an in vivo CRISPR therapy for Leber congenital amaurosis, a form of childhood blindness. Intellia Therapeutics is advancing in vivo editing for transthyretin amyloidosis and hereditary angioedema. Beam Therapeutics is developing base-editing therapies for sickle cell disease that may achieve even higher fetal hemoglobin levels without the need for ex vivo manipulation.
The expansion of Casgevy also establishes regulatory precedent. The FDA has now signaled that it is willing to approve CRISPR-based therapies for pediatric populations with severe, life-limiting genetic diseases, provided the evidence supports a favorable risk-benefit balance. This will influence the development timeline and regulatory strategy for dozens of pipeline programs.
Looking Forward
For the thousands of families raising children with sickle cell disease, the expanded approval of Casgevy represents hope — the possibility that a single intervention could free their child from a lifetime of pain, hospitalization, and progressive organ damage. But significant barriers remain. The treatment is complex, requiring specialized transplant centers with experience in stem cell collection, busulfan conditioning, and post-transplant care. Not all children will be eligible; those with significant end-organ damage or active infections may not qualify. And the high cost, even with insurance, can create access disparities.
As gene editing technology continues to mature, the hope is that future iterations of CRISPR therapy will be simpler, safer, and more accessible. In vivo editing approaches that deliver the CRISPR machinery directly to the bone marrow, without the need for stem cell harvest and chemotherapy conditioning, are in early clinical development. If successful, they could transform what is currently a months-long hospital ordeal into a single outpatient infusion.
For now, the FDA's decision gives pediatric hematologists a powerful new tool. Casgevy is no longer a therapy reserved for adolescents and adults — it is available to children, at an age when it can make the greatest difference.
|> Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients and families should consult with their healthcare providers about treatment options.